 "Vaccination, Coronavirus vaccine")
India’s government said on Thursday it has inked a deal with Hyderabad-based vaccine maker Biological-E for 300 million COVID-19 vaccine doses for 15 billion rupees ($205.62 million), the first such order for unapproved shots.
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson’s (JNJ.N) COVID-19 shot annually, said on Tuesday it entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company’s mRNA COVID-19 vaccine in India.
Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
